Doe v. Pharmacia & Upjohn Co.

879 A.2d 1088, 388 Md. 407, 2005 Md. LEXIS 475
CourtCourt of Appeals of Maryland
DecidedAugust 11, 2005
DocketMisc. No. 13, September Term, 2004
StatusPublished
Cited by55 cases

This text of 879 A.2d 1088 (Doe v. Pharmacia & Upjohn Co.) is published on Counsel Stack Legal Research, covering Court of Appeals of Maryland primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Doe v. Pharmacia & Upjohn Co., 879 A.2d 1088, 388 Md. 407, 2005 Md. LEXIS 475 (Md. 2005).

Opinion

RAKER, J.

In this Certified Question case, pursuant to the Maryland Uniform Certification of Questions of Law Act, Maryland Code (1974, 2002 Repl.Vol., 2004 Cum.Supp.), §§ 12-601 through 12-613 of the Courts and Judicial Proceedings Article, and Maryland Rule 8-305, the United States Court of Appeals for the Fourth Circuit has certified the following questions of Maryland law:

“(1) For purposes of a negligence cause of action, does a commercial manufacturer of two strains of HIV (‘HIV-1’ and ‘HIV-2’), which conducts blood tests on its employees who have been exposed to HIV while on the job, and which manufactures test kits for HIV-1, owe a legal duty to its employees’ spouses to exercise reasonable care in conducting testing, including testing for both strains of the virus?”
“(2) For purposes of a negligence or negligent misrepresentation cause of action, does a commercial manufacturer of two strains of HIV (‘HIV-1’ and ‘HIV-2’), which conducts blood tests of its employees who have been exposed to HIV while on the job, owe a legal duty to its employees’ spouses to exercise reasonable care in informing the employees of the nature of the test results, including the fact that a ‘false positive’ test result for HIV-1 may indicate an HIV-2 infection?”

*410 Our answer to both of these questions shall be NO. 1

I.

We recite the facts as set out in the Certification Order.

“Jane Doe has been married to, and living as husband and wife with, John Doe since 1971. Between 1974 and 1991, John Doe was employed by Pharmacia as a laboratory technician at its Montgomery County, Maryland, viral production facility. Pharmacia cultivated pathogens at this facility for use in diagnostic test strips manufactured and sold by Pharmacia and others. John Doe’s primary job responsibilities included the daily feeding, growing, and harvesting of pathogens for large scale propagation. Pharmacia closed this facility in 1991.
“In 1984, researchers discovered that the primary causative viral agent of acquired immune deficiency syndrome (‘AIDS’) is HIV. By 1986, two types of HIV, designated as ‘HIV-1’ and ‘HIV-2,’ had been discovered. The first reported case of HIV-2 in the United States was in 1987, and there have been few reported HIV-2 cases in the United States. Both HIV-1 and HIV-2 have the same modes of transmission and are associated with AIDS. Compared with persons infected with HIV-1, those with HIV-2 are less infectious early in the course of infection.
“Beginning in 1984, approximately 80% of the viral production at the Pharmacia facility where John Doe worked was HIV-1 and HIV-2. Pharmacia cultivated and harvested HIV cultures on a daily basis and shipped them to another facility for incorporation into a test for HIV antibodies. Between 1985 and 1991, John Doe was exposed to high concentrations of HIV-1 and HIV-2 while on the job.
“At some point around 1985, Pharmacia (through its agent) began testing its employees, including John Doe, who *411 were exposed to HIV in the workplace every six months. Pharmacia manufactured the test strips that were used in this testing. Although Pharmacia was aware of the existence of HIV-2, commercial test kits were not available in the United States to test for an injurious exposure to HIV-2 before 1991 because of the statistically insignificant incidence of the virus. Therefore, Pharmacia’s testing was limited to detection of HIV-1. However, Pharmacia possessed the materials, knowledge, and capability to manufacture its own test strips to detect HIV-2.
“The testing conducted by Pharmacia consisted of a two-part protocol whereby an initial screen (the Elisa test) would, if positive, be followed by a confirmatory test (the Western Blot) for HIV-1. By 1989, Pharmacia was aware that the HIV tests being used would detect core proteins present in both HIV-1 and HIV-2, and that while the HIV-2 proteins (among other factors) could cause a positive result on the Elisa test, the Western blot test would confirm only the presence of HIV-1. Thus, as of 1989, a person infected with HIV-2 could test positive on the Elisa test but negative on the Western blot test. This type of result was considered to be a ‘false positive’ for HIV-1.
“John Doe consistently tested negative until 1989, when he received a positive result on the Elisa test. John Doe was retested, and the result was negative. John Doe’s subsequent tests were negative.
“Pharmacia did not counsel or warn either John Doe, Jane Doe, or its testing agent about the potential negative ramifications of a ‘false positive’ test. However, Pharmacia (and/or its agent) did tell John Doe after the ‘false positive’ test that the Western Blot test failed to confirm the presence of HIV-1; that the test result could have been caused by factors unrelated to exposure to IIIV; that the test result did not indicate that he was infected with the virus that causes AIDS; and that the test result did not indicate a significant risk to his health. Neither Jane Doe nor John Doe was aware that a ‘false positive’ test could indicate an HIV-2 infection.
*412 “In October 2000, John Doe was admitted to the hospital where he was found to be suffering from multiple AIDS-like conditions. Although John Doe tested negative for HIV-1, he tested positive for HIV-2 and was diagnosed as having AIDS. John Doe became infected with HIV-2 while handling the virus as a Pharmacia employee.
“Upon learning that he was infected with HIV-2, John Doe immediately informed Jane Doe. Subsequent testing of Jane Doe revealed that she also is infected with HIV-2. Jane Doe was John Doe’s only sexual partner and was known as such by Pharmacia. Jane Doe became infected with HIV-2 because of unprotected marital relations with John Doe. The Does would not have engaged in unprotected marital relations had they been aware that John Doe was infected with HIV-2.
“Pharmacia was aware at times pertinent to this case that HIV-2 was a pathogen that could have significant consequences, including death for humans, and that it could be transmitted by sexual contact and exchange of body fluids. Pharmacia also knew that the spread of HIV-2 between sexual partners could be effectively prevented through behavior modification and the use of barrier devices. Pharmacia also learned, subsequent to the conclusion of John Doe’s employment, that at least one co-worker of John Doe’s at the Montgomery County facility had unexpectedly become infected with one or more lethal pathogens that had been propagated in that facility; however, despite having this knowledge, Pharmacia did not warn the Does of any danger.” (Citations and footnotes omitted.)

II.

Jane Doe filed a tort action in the Circuit Court for Montgomery County against Pharmacia & Upjohn Company, Inc. (“Pharmacia”). Pharmacia removed the case to the United States District Court for the District of Maryland and subsequently filed a motion to dismiss pursuant to Fed. Rule Civ. Pro. 12(b)(6). Ms.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Untitled Case
D. Maryland, 2026
Gomez v. Smart
D. Maryland, 2024
Heym v. APG Housing, LLC
D. Maryland, 2024
Hancock v. Mayor & Cty. Cncl. of Balt.
Court of Appeals of Maryland, 2022
Doe v. Loyola University
D. Maryland, 2021
Johnson v. PNC Bank
D. Maryland, 2020
Jane Doe v. Cochran
210 A.3d 469 (Supreme Court of Connecticut, 2019)
Estate of Schatz v. Univ. of Md., College Park
196 A.3d 74 (Court of Special Appeals of Maryland, 2018)
Kennedy Krieger Inst., Inc. v. Partlow
191 A.3d 425 (Court of Appeals of Maryland, 2018)
Chassels v. Krepps
174 A.3d 896 (Court of Special Appeals of Maryland, 2017)
May v. Air & Liquid Systems Corp.
129 A.3d 984 (Court of Appeals of Maryland, 2015)
Doe v. Salisbury University
123 F. Supp. 3d 748 (D. Maryland, 2015)

Cite This Page — Counsel Stack

Bluebook (online)
879 A.2d 1088, 388 Md. 407, 2005 Md. LEXIS 475, Counsel Stack Legal Research, https://law.counselstack.com/opinion/doe-v-pharmacia-upjohn-co-md-2005.